YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

The Stimulatory Effect of PDE Inhibitors on $PGE_2$-Induced Osteoclastogenesis

PDE 저해제에 의한 $PGE_2$의 파골세포 분화 유도 증강효과

  • Published : 2007.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

To determine the regulatory roles of phosphodiesterase (PDE) inhibitors on $PGE_2$-induced osteoclastogenesis, we investigated the effect of PDE inhibitors on osteoclast formation in the presence of $PGE_2$. Among PDE isozyme specific inhibitors, milrinone, a selective PDE3 inhibitor, and rolipram, a specific PDE4 inhibitor, increased $PGE_2$-induced osteoclast formation in cocultures of mouse bone marrow cells and osteoblasts. To verify that whether the PDE3 and PDE4 inhibitors act indirectly on osteoblasts, we measured the concentration of intracellular cAMP in osteoblasts. Treatment of milrinone or rolipram increased $PGE_2$-stimulated cAMP levels in osteoblasts. Furthermore, northern blot analysis revealed that the PDE3 and PDE4 inhibitors works synergistically with $PGE_2$ to increase the expression of TRANCE mRNA in osteoblasts. On the contrary, the PDE3 and PDE4 inhibitors did not augment the number of osteoclasts differentiated from bone marrow cells by $PGE_2$. In conclusion, the stimulation of $PGE_2$-induced osteoclast formation by the PDE3 and PDE4 inhibitors are attributable to their indirect effect on osteoblasts, not to their direct effect on bone marrow-derived osteoclast precursors.

Keywords

References

  1. Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J. and Suda, T. : Osteoblastic cells are involved in osteoclast formation. Endocrinology 123, 2600 (1988)
  2. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T. and Martin, T. J. : Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345 (1999)
  3. Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick. J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F S. 3rd, Frankel, W. N., Lee, S. Y. and Choi, Y. : TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. BioI. Chem. 272, 25190 (1997)
  4. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N. and Suda, T. : Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. SCI. USA 95, 3597 (1998)
  5. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J. and Boyle, W. J. : Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165 (1998)
  6. Kaji, H., Sugimoto, T., Kanatani, M., Fukase, M., Kumegawa, M. and Chihara, K. : Prostaglandin $E_2$ stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase.J. Bone Miner. Res. 11, 62 (1996)
  7. Wani, M. R, Fuller, K., Kim, N. S., Choi, Y. and Chambers, T. : Prostaglandin $E_2$ cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. Endocrinology 140, 1927 (1999)
  8. Take, I., Kobayashi, Y., Yamamoto, Y., Tsuboi, H., Ochi, T., Uematsu, S., Okafuji, N., Kurihara, S., Udagawa, N. and Takahashi, N. : Prostaglandin $E_2$ strongly inhibits human osteoclast formation. Endocrinology 146, 5204 (2005) https://doi.org/10.1210/en.2005-0451
  9. Li, L., Pettit, A. R., Gregory, L. S. and Forwood, M. R. : Regulation of bone biology by prostaglandin endoperoxide H synthases (PGHS): a rose by any other name. Cytokine Growth Factor Rev. 17, 203 (2006) https://doi.org/10.1016/j.cytogfr.2006.01.005
  10. Antoni, F. A. : Molecular diversity of cyclic AMP signaling. Front Neuroendocrinol. 21, 103 (2000)
  11. Essayan, D. M. : Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol. 108, 671 (2001) https://doi.org/10.1067/mai.2001.117052
  12. Bender, A. T. and Beavo, J. A. : Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacal Rev. 58, 488 (2006) https://doi.org/10.1124/pr.58.3.5
  13. Park, H., Young Lee, S., Lee, D. S. and Yim, M. : Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts. Biochem. Biophys. Res. Commun. 354, 178 (2007)
  14. Kondo, H., Guo, J. and Bringhurst, F. R. : Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J. Bone Miner. Res. 17, 1667 (2002)
  15. Fu, Q., Jilka, R. L., Manolagas, S. C. and O'Brien, C. A. : Parathyroid hormone stimulates receptor activator of NF-${\kappa}B$ ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J. BioI. Chem. 277, 48868 (2002)